AVIRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Atea Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$4.39+0.07 (+1.62%)
Close on Oct 19, 2026
- Market cap
- $351.42M
- P/E (TTM)
- –
- Dividend yield
- –
Atea Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Atea Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $352.10M | $166.30M |
| Enterprise Value | $132.63M | $88.19M |
| PB Ratio | 1.72 | 2.03 |
| P/TBV Ratio | 1.72 | 2.29 |
Income (trailing twelve months)
| Measure | Atea Pharmaceuticals | Industry median |
|---|---|---|
| Operating Income | -$183.61M | -$21.40M |
| Pretax Income | -$171.79M | -$14.34M |
| Net Income | -$165.29M | -$22.46M |
| EBITDA | -$183.19M | -$16.91M |
| EPS (Diluted) | -$2.08 | -$0.83 |
Returns
| Measure | Atea Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -58.1% | -53.2% |
| Return on Assets (ROA) | -53.0% | -40.9% |
| Return on Capital Employed (ROCE) | -89.9% | -38.1% |
Balance sheet
| Measure | Atea Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $219.47M | $61.43M |
| Net Cash (Debt) | $219.47M | $15.35M |
| Net Cash Per Share | $2.74 | $0.66 |
| Equity (Book Value) | $204.16M | $49.09M |
| Book Value Per Share | $2.55 | $1.37 |
| Tangible Book Value | $204.16M | $23.52M |
| Working Capital | $200.54M | $76.81M |
Financial position
| Measure | Atea Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 8.13 | 3.34 |
| Quick Ratio | 7.80 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Atea Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$152.07M | -$12.35M |
Efficiency
| Measure | Atea Pharmaceuticals | Industry median |
|---|---|---|
| Profits Per Employee | -$3.01M | -$703.34K |
| Employee Count | 55 | 74 |
Dividends and yields
| Measure | Atea Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -46.9% | -23.3% |
Shares
| Measure | Atea Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 80,204,700 | 58,127,000 |
| Shares Change (YoY) | -6.33% | 10.9% |
| Shares Change (QoQ) | 0.22% | 0.54% |
| Float | 65,449,900 | 49,136,700 |
| Shares Held by Insiders | 18.4% | 11.6% |
| Shares Held by Institutions | 74.1% | 59.4% |
Taxes
| Measure | Atea Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | -$6.50M | $79.87K |
Scores
| Measure | Atea Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 2.32 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Atea Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.